Sign in

NCT05175547CompletedPhase 3

Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke

Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke (CLEVER)

Source: ClinicalTrials.gov · Last updated 7 Jan 2025

Brief summary (registry, in English)

The CLEVER Study is a prospective, 2-arm, randomized, single-center pilot study to assess the safety and efficacy of intensive blood pressure control using Clevidipine (on-label use) in AIS patients undergoing standard of care mechanical thrombectomy (MT) within 24-hours of symptoms onset.

Status (registry)
Completed
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
80 (actual)
First submitted
23 Nov 2021
Start date
30 Oct 2021
Primary completion date
28 Feb 2024
Lead sponsor
ProMedica Health System
Diseases
Stroke
NCT number
NCT05175547

What you commit to

  • Study type: Interventional · Phase 3
  • Participants enrolled: 80
  • From 30 Oct 2021 to the primary completion date, 28 Feb 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • 9\. Concurrent enrollment in another trial that could confound the results of this study

Other illness

  • 1\. Presence of any hemorrhage and/or ASPECT score ≤6 on baseline head CT scan
  • 7\. Severe arrhythmias, unstable cardiac function
  • 8\. Any terminal medical condition with life expectancy less than 6 months

Other

  • 2\. Pregnant or lactating
  • 3\. Acute traumatic brain injury
  • 4\. Patient on active dialysis
  • 5\. Intracranial neoplasm
  • 6\. Acute or recent STEMI in the last 30 days

Who the study is looking for

  • 1\. Age 18 or older
  • 2\. Acute hypertension (systolic blood pressure of greater than 140 mmHg) at recanalization
  • 3\. Anterior circulation ischemic stroke symptoms and confirmed occlusion (ICA, M1, or M2) on angiogram with mechanical thrombectomy initiated within 24 hours since last known well
  • 4\. Success revascularization score of mTICI 2c or higher after mechanical thrombectomy
  • 5\. ASPECTS score of greater than 6
  • 6\. Premorbid mRS 0-4
  • 7\. Signed informed consent within 30 minutes from end of MT procedure.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
ProMedica Toledo Hospital
Coordinator of this site? Confirm its status		ToledoUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.